Product recall litigation — will the UK follow the US trend?
By Stuart Young
Product recalls have a damaging reputational effect and have huge financial implications for the manufacturer arising from a lack of consumer confidence. In the US, class actions following on from product recalls are a significant risk for many automotive companies. The volume of claimants involved, the availability of punitive damages and the scale of the litigation impose an increased financial burden in addition to the recall itself.
As the automotive industry becomes more and more standardised, product recalls affect more models and brands than ever before. As Prof David Bailey notes, large-scale recalls are set to remain a feature of the industry, ‘given that it can cost anywhere up to $1bn [£590m] to get a genuinely new car to market’. He said: ‘Car makers are increasingly using common components and platforms across models and brands so as to reduce costs. So if something goes wrong with an accelerator pedal or a seat mechanism, it doesn’t just affect one model but perhaps six or seven, and across different brands.’
He added: ‘This can have a significant impact on firms — Toyota, for example, saw a fall in its share price of more than 20 per cent, worth some $35bn, in the wake of the 2009 and 2010 recalls. Fixing the problem literally cost the company billions of dollars.’ …
Click on the link below to read the rest of the Wragge Lawrence Graham & Co briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.